Michelson Diagnostics, the UK based medical device company focused on multi-beam optical coherence tomography (OCT) technology, has announced positive results from the successfully completed multi-centre, prospective clinical trial for the diagnosis of basal cell carcinoma using VivoSight OCT to be presented at the upcoming American Academy of Dermatology's (AAD) 72nd annual meeting in Denver, Colorado, 21 March to 25 March 2014.

Papers by Dr med. Julia Welzel, Dr. med. Martina Ulrich discussing results from the clinical study will be presented in the AAD Conference Session F153 ‘Non-Invasive Imaging in Dermatology’ on March 25.

The presented results support Michelson Diagnostics vision that its VivoSight OCT system has the potential to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect the skin, and in particular non-melanoma skin cancer.

The AAD supports the highest-quality patient care by developing and presenting information that enhances continuing education in dermatology.